All articles tagged with #neurodegeneration
Scientists developed a tool to temporarily boost mitochondrial activity in the brain, and in mouse models of neurodegenerative disease this restored memory performance, suggesting energy failure in neurons may drive cognitive decline and could become a new therapeutic target—though the approach is still far from human use and requires extensive safety and efficacy studies.
A Baylor College of Medicine study suggests increasing cellular tubulin can steer Tau and alpha-synuclein away from harmful aggregates toward healthy microtubule activity, offering a potential therapeutic strategy for Alzheimer’s and Parkinson’s by boosting tubulin rather than blocking condensate formation.
A study of 1,647 middle-aged and older adults found that closer adherence to the MIND diet—a Mediterranean-DASH blend rich in antioxidants—was linked to less brain tissue loss, especially gray matter, and less ventricular enlargement over about 12 years, equating to roughly 2.5 years slower brain aging; results varied with some foods (whole grains linked to faster gray-matter decline; cheese linked to slower decline), and causality isn’t established.
Researchers at Heidelberg and Shandong University identified a toxic interaction between NMDA receptors and the TRPM4 channel—described as a 'death complex'—that worsens Alzheimer’s in a mouse model. They showed FP802, a novel neuroprotective drug, can block this interaction, slowing neurodegeneration, preserving synapses and mitochondria, and reducing amyloid deposits, offering a therapeutic approach distinct from amyloid removal. While promising, further pharmacological development, toxicology work, and clinical trials are needed before it could be used in humans, and researchers are also exploring potential ALS applications.
A new study suggests Alzheimer's may start when amyloid beta competes with tau for binding to microtubules in neurons, displacing tau and destabilizing the cell’s transport system. This microtubule nexus could unify amyloid- and tau-centered theories and open pathways for therapies that target tau displacement from microtubules.
Emory researchers in mouse models of leaky gut and disease show very small numbers of live gut bacteria can reach the brain, with evidence that the vagus nerve serves as the main route; blocking the nerve reduced brain bacterial presence, suggesting a gut-to-brain transmission axis influenced by diet and genetics and potentially reversible by restoring gut integrity. The findings, published in PLOS Biology, are not yet known to occur in humans and the bacteria were present in very low amounts, leaving open questions about their role in inflammation or disease and whether future gut-targeted therapies could affect brain conditions.
UC Santa Cruz researchers show the overlooked P3 peptide (also called Amyloid α), produced from the same amyloid precursor protein as amyloid beta, can form amyloid deposits and may contribute to neuron damage, challenging the Aβ-centric view of Alzheimer’s and suggesting new therapeutic avenues.
A 12-year Framingham Heart Study Offspring analysis found higher adherence to the MIND diet—rich in leafy greens, berries, nuts, whole grains, fish, poultry, olive oil, and moderate wine—was associated with slower brain aging on MRI, including reduced gray matter loss and less ventricular expansion. Each 3-point rise in MIND score correlated with about 0.279 cm³/year slower gray matter loss (roughly 20% less aging and ~2.5 years) and −0.071 cm³/year slower ventricular expansion (about 1 year). Benefits were strongest for berries and poultry; sweets and fried foods linked to worse changes. The study is observational, with recall bias and a predominantly White cohort limiting causal claims, but supports the brain-health potential of the MIND diet as part of a healthy lifestyle.
A UCLA Health study links long-term residential exposure to the pesticide chlorpyrifos with a more than 2.5-fold increase in Parkinson’s disease risk; animal experiments show chlorpyrifos damages dopamine neurons, triggers alpha-synuclein buildup, brain inflammation, and disrupts autophagy, the cellular protein-cleanup system, suggesting mechanisms and potential therapeutic targets and highlighting the importance of monitoring exposed individuals.
A Cedars-Sinai study found the pneumonia-causing bacterium Chlamydia pneumoniae in the retina, with higher bacterial loads in individuals with Alzheimer’s disease; the bacteria may amplify brain pathology by triggering the NLRP3 inflammasome, increasing inflammation and amyloid beta, and the retina could serve as a noninvasive biomarker for disease status while anti-inflammatory or antibiotic strategies are being explored, though questions remain about how and when infection occurs.
A large observational study from Emory University analyzing about 27.8 million US seniors over 18 years links higher 5-year average PM2.5 exposure to increased Alzheimer's disease risk, suggesting direct brain effects beyond traditional risk factors. Using ZIP-code pollution estimates, the researchers found a strong association even after adjusting for comorbidities, with stroke appearing to heighten vulnerability. While causality can’t be proven, the findings support the public health case for reducing air pollution to help lower dementia risk.
A Danish study following 17,711 people over 12 years found that depression is more common years before a diagnosis of Parkinson's disease or Lewy body dementia, with rates rising about eight years prior and remaining elevated after diagnosis, strongest for Lewy body dementia. By comparing with rheumatoid arthritis, chronic kidney disease, and osteoporosis, researchers suggest the link isn’t solely due to disability. The study shows association, not causation, and supports screening older adults with new or late-onset depression for early neurodegenerative signs to enable earlier care and research.
Aging clocks applied to single neuron types in C. elegans reveal neuron-type–specific biological ages, with environmentally exposed ciliated amphid neurons aging fastest and degenerating earlier. Reducing translation slows degeneration in fast-aging neurons, and neuronal aging patterns correlate with human brain aging while anticorrelating with known geroprotective interventions. An in silico CMAP screen identifies potential neuroprotective compounds, notably syringic acid and vanoxerine, while some agents (e.g., WAY-100635, Bay K8644) can be neurotoxic. The study suggests neuron-type aging trajectories can guide protective interventions and risk-factor identification for neurodegeneration across species.
Researchers show the enzyme OTULIN acts as a master regulator of tau production in neurons: blocking OTULIN reduced tau levels and removing its gene even halted tau synthesis, while RNA analysis revealed widespread changes in gene activity, notably in inflammatory pathways; the findings open a potential new route to slow brain aging and Alzheimer's, but safety concerns remain since OTULIN and tau have essential functions and much more research is needed.
A study from University Hospitals, Case Western Reserve University, and the Cleveland VA reversed advanced Alzheimer's in mice by stabilizing brain NAD+ energy balance with the compound P7C3-A20, achieving full cognitive recovery and suggesting a potential amyloid-independent therapy for humans. While promising, results in animals don’t guarantee human success; the team aims for phase I safety trials within about 18 months and envisions broader use for neurodegeneration, alongside lifestyle measures and caregiver support.